ClinicalTrials.gg
CompletedNCT02250612SYLTAGUpdated Jan 6, 2021Results posted

SYL040012, Treatment for Open Angle Glaucoma

A Phase 2 interventional study of 1 drop of 0.375% SYL040012 (bamosiran) and 1 drop of 0.750% SYL040012 (bamosiran) in Open Angle Glaucoma and Ocular Hypertension, sponsored by Sylentis, S.A.. Completed at 21 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.

Enrollment
12th of 35
184 · median 107
Started
2014
with 2 others
Phase 2
2 of 47
none open now
Registered
25th of 47
by date
Lead sponsor
2 of 47
Sylentis, S.A.

Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 12th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2014, is one of 2 in phase 2, and was the 25th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Glaucoma, Open-Angle with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.

03

Conditions studied

  • Open Angle Glaucoma
  • Ocular Hypertension

Keywords

  • SYL040012
  • bamosiran
  • siRNA
  • RNAi
  • Glaucoma
  • Ocular hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years of either sex
  • Good or fair general health as assessed by the investigator.
  • Signed prior to any clinical trial-related procedures
  • Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)
  • Post-washout mean IOP above target range
  • BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200)
  • Stable visual field
  • Central corneal thickness 480-620 μm
  • Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • Females of not willing to use a medically acceptable method
  • systemic disease
  • Changes of systemic medication that could have a substantial effect on IOP
  • Known to any component of the formulations
  • Unable to comply with the clinical trial requirements
  • Clinically significant abnormalities in laboratory tests
  • Severe visual field defect
  • Any secondary glaucoma
  • Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles.
  • IOP ≥ 35 mm Hg in any eye
  • Previous non-laser glaucoma surgery or glaucoma laser procedures (e.g., laser trabeculoplasty) and refractive surgery
  • Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6 months prior to Baseline
  • Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis
  • Clinically significant ocular disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    SYL040012 (bamosiran) 0.375% eye drops

    1 drop in each eye once daily for 28 consecutive days

    Drug: 1 drop of 0.375% SYL040012 (bamosiran)

  • Experimental
    SYL040012 (bamosiran) 0.750% eye drops

    1 drop in each eye once daily for 28 consecutive days

    Drug: 1 drop of 0.750% SYL040012 (bamosiran)

  • Experimental
    SYL040012 (bamosiran) 1.125% eye drops

    1 drop in each eye once daily for 28 consecutive days

    Drug: 1 drop of 1.125% SYL040012 (bamosiran)

  • Experimental
    SYL040012 (bamosiran) 1.5% eye drops

    1 drop in each eye once daily for 28 consecutive days

    Drug: 1 drop of 1.5% SYL040012 (bamosiran)

  • Active comparator
    Timolol maleate 0.5% ophthalmic solution

    1 drop in each eye twice daily for 28 consecutive days

    Drug: 1 drop of 0.5 % timolol maleate

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm

    Time frame: Baseline and Day 28

Secondary outcomes

  1. Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm

    Time frame: Baseline and Day 14

  2. Change From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm

    The GQL-15 is a 15 item, 4-domain tool. GQL-15 scoring ranges from 0 to 75. Higher scores indicate poorer quality of life.

    Time frame: Baseline and Day 29

07

Results

Posted Nov 4, 2020

Participant flow

Participant flow — Overall Study
MilestoneSYL040012 (Bamosiran) 0.375% Eye DropsSYL040012 (Bamosiran) 0.750 % Eye DropsSYL040012 (Bamosiran) 1.125% Eye DropsSYL040012 (Bamosiran) 1.5% Eye DropsTimolol Maleate 0.5% Ophthalmic Solution
Started3740373337
Completed3638353336
Not completed12201

Outcome measures

PrimaryChange From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
Time frame:
Baseline and Day 28
Reported as:
Mean · mmHg
Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
mmHgSYL040012 (Bamosiran) 0.375 % Eye DropsSYL040012 (Bamosiran) 0.75 % Eye DropsSYL040012 (Bamosiran) 1.125% Eye DropsSYL040012 (Bamosiran) 1.5% Eye DropsTimolol Maleate 0.5% Ophthalmic Solution
Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm-2.4 ± 2.6-3.2 ± 3.9-3.1 ± 2.5-3.1 ± 3.2-6.1 ± 2.2
Statistical analysis
  • SYL040012 (Bamosiran) 1.125% Eye Drops vs SYL040012 (Bamosiran) 1.5% Eye Drops · ANCOVA · p = 0.93
  • SYL040012 (Bamosiran) 0.75 % Eye Drops vs SYL040012 (Bamosiran) 1.5% Eye Drops · ANCOVA · p = 0.92
  • SYL040012 (Bamosiran) 0.375 % Eye Drops vs SYL040012 (Bamosiran) 1.5% Eye Drops · ANCOVA · p = 0.23
  • SYL040012 (Bamosiran) 0.75 % Eye Drops vs SYL040012 (Bamosiran) 1.125% Eye Drops · ANCOVA · p = 0.85
  • SYL040012 (Bamosiran) 0.375 % Eye Drops vs SYL040012 (Bamosiran) 1.125% Eye Drops · ANCOVA · p = 0.25
  • SYL040012 (Bamosiran) 0.375 % Eye Drops vs SYL040012 (Bamosiran) 0.75 % Eye Drops · ANCOVA · p = 0.18
SecondaryChange From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
Time frame:
Baseline and Day 14
Reported as:
Mean · mmHg
Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
mmHgSYL040012 (Bamosiran) 1.5% Eye DropsSYL040012 (Bamosiran) Eye Drops 1.125%SYL040012 (Bamosiran) Eye Drops 0.75%SYL040012 (Bamosiran) 0.375 % Eye DropsTimolol Maleate 0.5% Ophthalmic Solution
Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm-2.4 ± 2.6-2.9 ± 2.4-2.5 ± 2.1-2.4 ± 3.1-5.8 ± 1.9
Statistical analysis
  • SYL040012 (Bamosiran) 1.5% Eye Drops vs SYL040012 (Bamosiran) Eye Drops 1.125% · ANCOVA · p = 0.94
  • SYL040012 (Bamosiran) 1.5% Eye Drops vs SYL040012 (Bamosiran) Eye Drops 0.75% · ANCOVA · p = 0.38
  • SYL040012 (Bamosiran) 1.5% Eye Drops vs SYL040012 (Bamosiran) 0.375 % Eye Drops · ANCOVA · p = 0.85
  • SYL040012 (Bamosiran) Eye Drops 1.125% vs SYL040012 (Bamosiran) Eye Drops 0.75% · ANCOVA · p = 0.412
  • SYL040012 (Bamosiran) Eye Drops 1.125% vs SYL040012 (Bamosiran) 0.375 % Eye Drops · ANCOVA · p = 0.79
  • SYL040012 (Bamosiran) Eye Drops 0.75% vs SYL040012 (Bamosiran) 0.375 % Eye Drops · ANCOVA · p = 0.28
SecondaryChange From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm

The GQL-15 is a 15 item, 4-domain tool. GQL-15 scoring ranges from 0 to 75. Higher scores indicate poorer quality of life.

Time frame:
Baseline and Day 29
Reported as:
Mean · units on a scale
Change From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm
units on a scaleSYL040012 (Bamosiran) 1.5% Eye DropsSYL040012 (Bamosiran) 1.125% Eye DropsSYL040012 (Bamosiran) 0.75% Eye DropsSYL040012 (Bamosiran) Eye Drops 0.375%Timolol Maleate 0.5% Ophthalmic Solution
Change From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm20 ± 8.2820.7 ± 7.6819.4 ± 6.3422 ± 9.6518.7 ± 6.21

Adverse events

Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SYL040012 (Bamosiran) Eye Drops Dose A0/37 (0%)0/37 (0%)4/37 (10.8%)
SYL040012 (Bamosiran) Eye Drops Dose B0/40 (0%)0/40 (0%)9/40 (22.5%)
SYL040012 (Bamosiran) Eye Drops Dose C0/37 (0%)0/37 (0%)6/37 (16.2%)
SYL040012 (Bamosiran) Eye Drops Dose D0/33 (0%)0/33 (0%)2/33 (6.1%)
Timolol Maleate 0.5% Ophthalmic Solution0/37 (0%)0/37 (0%)2/37 (5.4%)
Most frequent other events
Most frequent other events
EventSYL040012 (Bamosiran) Eye Drops Dose ASYL040012 (Bamosiran) Eye Drops Dose BSYL040012 (Bamosiran) Eye Drops Dose CSYL040012 (Bamosiran) Eye Drops Dose DTimolol Maleate 0.5% Ophthalmic Solution
HeadacheNervous system disorders1/371/403/371/330/37
Conjunctival hyperaemiaEye disorders1/370/403/372/331/37
Ocular discomfortEye disorders0/373/400/371/330/37
Eye pruritusEye disorders2/371/400/370/331/37
Instillation site painInvestigations0/370/400/370/332/37
NasopharyngitisInfections and infestations2/370/401/371/330/37
Lacrimation increasedEye disorders0/372/400/370/330/37
Vision blurredEye disorders0/372/400/370/331/37
ToothacheGastrointestinal disorders0/372/400/370/330/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)SYL040012 (Bamosiran) Eye Drops Dose ASYL040012 (Bamosiran) Eye Drops Dose BSYL040012 (Bamosiran) Eye Drops Dose CSYL040012 (Bamosiran) Eye Drops Dose DTimolol Maleate 0.5% Ophthalmic SolutionTotal
Mean60.7 ± 10.459.4 ± 12.961.5 ± 10.162.4 ± 11.160.2 ± 11.560.8 ± 11.18
Sex: Female, Male
Sex: Female, Male(Participants)SYL040012 (Bamosiran) Eye Drops Dose ASYL040012 (Bamosiran) Eye Drops Dose BSYL040012 (Bamosiran) Eye Drops Dose CSYL040012 (Bamosiran) Eye Drops Dose DTimolol Maleate 0.5% Ophthalmic SolutionTotal
Female2524222424119
Male12161591365
08

Study locations

21 sites
  • Sall Research Medical Center
    Artesia, California 90701, United States
  • North Bay Eye Associates
    Petaluma, California 94954, United States
  • Eye Care Centers Management, Inc (Clayton Eye Center)
    Morrow, Georgia 30260, United States
  • Taustin Eye Center
    Louisville, Kentucky 40217, United States
  • East Tallin Central Hospital
    Tallin, 10138, Estonia
  • Eye Clinic Dr. Krista Turman
    Tallin, 13419, Estonia
  • Tartu University Hospital
    Tartu, 50406, Estonia
  • Universitaetsklinikum Freiburg
    Freiburg, 79106, Germany
  • University Clinic Magdeburg
    Magdeburg, 39106, Germany
  • Klinikum der Universität München
    München, 80336, Germany
  • Universitätsklinikum Münster
    Münster, D-48149, Germany
  • University Hospital Regensburg
    Regensburg, 93053, Germany
  • Hospital de Torrevieja
    Torrevieja, Alicante 03186, Spain
  • Hospital de Jerez
    Jerez de la Frontera, Cádiz 11407, Spain
  • Clinica Universidad Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital Clinic
    Barcelona, 08036, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Clínico San Carlos
    Madrid, 28040, Spain
  • Complejo Hospitalario de Pontevedra
    Pontevedra, 36001, Spain
  • Instituto de Oftalmobiología Aplicada
    Valladolid, 47011, Spain
  • Hospital Universitario Miguel Servet
    Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Aug 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2014
First posted
Sep 26, 2014
Start
Oct 2014
Primary completionActual
Aug 2015
CompletionActual
Jan 2016
Results first posted
Nov 4, 2020
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02250612
Lead sponsor
Sylentis, S.A.
Responsible party
Sponsor
First posted
Sep 26, 2014
Start date
Oct 2014
Primary completion
Aug 2015
Completion
Jan 2016
Results posted
Nov 4, 2020
Last update
Jan 6, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bamosiran

Start the discussion